The transition from study design to execution often stalls when biotech teams struggle to identify CROs capable of handling highly specific experimental protocols. Current manual vetting processes consume significant resources, frequently delaying drug development timelines. ModernVivo’s new platform addresses this bottleneck by evaluating specific models, endpoints, and protocol requirements rather than relying on broad therapeutic categories.

For pharmaceutical teams, the marketplace provides access to a pre-vetted network of vendors throughout North America, Europe, and Asia-Pacific. The system simplifies the search by identifying partners whose technical expertise aligns with the project’s granular needs. CROs benefit by receiving qualified leads that match their existing capabilities, increasing visibility for high-fit opportunities.

ModernVivo CEO Ian Levine noted that the platform is designed to bridge the gap between initial design and experimental execution. By integrating this service with the company’s existing literature intelligence software, ModernVivo aims to create a more seamless development pipeline. The marketplace is free for both existing users of the ModernVivo Scholar platform and new researchers, with the ultimate objective of accelerating the timeline for moving potential treatments into clinical trials.